With a working knowledge of regulatory requirements and a strong understanding of life sciences, Xin Tao works closely with clients in the consumer and life sciences industries to navigate the evolving federal and state regulatory environments and develop innovative regulatory strategies to commercialize products made with emerging technologies.

Xin's background in biochemistry and biophysics informs his science-based food and drug law practices. His unique ability in understanding and interpreting the complex scientific issues as they relate to the governing regulatory requirements helps clients with all phases of product development, manufacturing, and marketing. He advises clients on food and drug law with a particular focus on novel food and drug applications that require U.S. Food and Drug Administration (FDA) review (e.g., food additive petition, food contact notification, and new drug applications) and FDA current good manufacturing practice (cGMP) compliance for foods, dietary supplements, and pharmaceuticals.

Xin is actively involved in a number of organizations that serve Chinese legal and life sciences professionals in the Washington, D.C. region, including the Sino-American Pharmaceutical Professionals Association and the Washington, D.C. Chinese Legal Association. Xin is a frequent speaker and contributor to industry publications in both the United States and China. He is adept at assisting both Chinese food and drug companies doing business in the United States and U.S. clients doing business in China. Xin is increasingly expanding his knowledge of China Food and Drug Administration's (CFDA) regulatory regime as it pertains to his clients.

During law school, Xin worked as a regulatory scientist at an international law firm and served as an executive editor of the Georgetown Environmental Law Review.